Joseph Shanahan, MD
Rheumatology · Durham, NCNPI 1043394901
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $313,292 of the $406,889 with a category attached, or 77.0%. It is spread thinly across 29 manufacturers, the largest accounting for just 22.3%. Reporting peaked in 2019 at $164,061 and has fallen 88.6% since, to $18,714 in 2025. Among rheumatology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 815 payments — averaging $499.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$91K
- Lilly USA, LLC$88K
- Bristol Myers Squibb$63K
- Novartis$62K
- AbbVie$39K
- Amgen$37K
- plus $26K from 23 others
Across 12 payments — averaging $6826.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$48K
- Astrazeneca UK Limited$14K
- Bristol Myers Squibb$9K
- Genentech, Inc.$7K
- Ablynx NV$4K
What the payments were for
- Consulting fees$34,2638%
- Speaking & faculty fees$313,29277%
- Travel & lodging$42,95011%
- Food & beverage$16,3224%
- Education$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 81 | $90,928 |
| Lilly USA, LLC | 170 | $87,571 |
| Bristol Myers Squibb | 49 | $63,207 |
| Novartis | 97 | $61,995 |
| AbbVie | 155 | $39,479 |
| Amgen(2 entities) | 125 | $37,464 |
| Regeneron Healthcare Solutions, Inc. | 46 | $12,602 |
| Johnson & Johnson(2 entities) | 18 | $5,436 |
| UCB, Inc. | 7 | $4,601 |
| Boehringer Ingelheim | 6 | $1,720 |
| AstraZeneca(2 entities) | 8 | $452 |
| Sanofi | 9 | $355 |
| Mallinckrodt Hospital Products Inc. | 2 | $168 |
| Pfizer | 9 | $146 |
| Radius Health, Inc. | 6 | $135 |
| Sobi, Inc | 1 | $106 |
| Janssen Scientific Affairs, LLC | 2 | $102 |
| E.r. Squibb & Sons, L.L.C. | 6 | $100 |
| Fresenius Kabi USA, LLC | 3 | $77 |
| Aurinia Pharma U.S., Inc. | 4 | $63 |
| Genentech USA, Inc. | 2 | $41 |
| Merck | 1 | $23 |
| Covidien LP | 1 | $22 |
| Invivyd Inc | 1 | $19 |
| Organon | 2 | $19 |
| Sonex Health, Inc. | 1 | $19 |
| Arcutis Biotherapeutics, Inc. | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$406,889 in reported general payments places this provider in the 95th percentile of 210 rheumatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 158 | $1,675,842 |
| Xeljanz XrTofacitinib Citrate | 132 | $767,174 |
| Orencia ClickjectAbatacept | 40 | $373,333 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 40 | $316,377 |
| OtezlaApremilast | 63 | $304,944 |
| Enbrel SureclickEtanercept | 38 | $279,811 |
| Taltz AutoinjectorIxekizumab | 33 | $225,320 |
| Cosentyx Sensoready PenSecukinumab | 30 | $217,999 |
| BenlystaBelimumab | 39 | $204,629 |
| NucalaMepolizumab | 16 | $177,064 |
| KevzaraSarilumab | 22 | $141,230 |
| RinvoqUpadacitinib | 18 | $133,949 |
| Enbrel MiniEtanercept | 12 | $125,904 |
| TymlosAbaloparatide | 33 | $123,358 |
| SimponiGolimumab | 15 | $93,912 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBenlysta, Nucala | $90,928 | $381,69355 claims |
| AmgenOtezla | $37,464 | $304,94463 claims |
| SanofiKevzara | $355 | $141,23022 claims |
| AbbVieRinvoq | $39,479 | $133,94918 claims |
| Radius Health, Inc.Tymlos | $135 | $123,35833 claims |
| Johnson & JohnsonSimponi | $5,436 | $93,91215 claims |
| UCB, Inc.Cimzia (2 Pack) | $4,601 | $59,46711 claims |
| Hikma Pharmaceuticals USAMitigare | $11 | $14,88417 claims |
| PfizerPaxlovid | $146 | $1,42911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 210 rheumatology providers in North Carolina.
Other rheumatology in Durham
- Ralph SnydermanDurham$1.3M
- Megan ClowseDurham$72K
- Virginia KrausDurham$31K
- Laura SchanbergDurham$20K
- David LeverenzDurham$11K
- Gordon LamCharlotte$2.7M
- Wendy SimmonsWilmington$462K
- Andrew LasterCharlotte$421K
- Ana RossRaleigh$417K
- Gwenesta MeltonFayetteville$410K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.